Literature DB >> 22652272

Correlation of methylenetetrahydrofolate reductase polymorphisms with homocysteine metabolism in healthy Lebanese adults.

Rami A Mahfouz1, Najwa K Cortas, Khalil M Charafeddine, Rabab N Abdul Khalik, Doja S Sarieddine, Raneem H Kadi, Rose T Daher.   

Abstract

Hyperhomocysteinemia is associated with several vascular and teratogenic conditions. Determinants of total homocysteine concentrations include genetic and nutritional factors. This study assesses the relation between homocysteine concentrations and MTHFR gene polymorphisms at two common alleles (C677T (rs1801133) and A1298C (rs1801131)) as well as other predictors of homocysteine (folate, vitamin B(12), body mass index (BMI), age, and gender) in a group of healthy Lebanese: 109 males and 124 females aged 17-55years. We used serum for the determination of homocysteine, folate and vitamin B(12) levels and blood drawn in EDTA tubes for molecular analysis of MTHFR polymorphisms. Hyperhomocysteinemia was present in 59/233 (25.3%) of the subjects, with male/female ratio of 1.95. Multivariable regression analysis showed that homocysteine levels were negatively related to folate and vitamin B(12) and positively related to male gender and C677T homozygosity; but not A1298C polymorphism, BMI or age. The prevalence of wild, heterozygous, and homozygous C677T genotypes was 45.0%, 43.3% and 11.6%, respectively; with a carrier frequency of 54.9% and allelic frequency of 33.3%. The A1298C genotypic prevalence was 39.5%, 30.9%, and 29.6% respectively; with a carrier frequency of 60.5% and allelic frequency of 45.1%. C677T/A1289C compound heterozygosity was present in 47/233 (20.2%) of volunteers. In this first pilot study, gender, folate, vitamin B(12) and C677T mutational status could explain around 32% of homocysteine variations. Future larger studies are recommended to investigate other predictors of homocysteine variation and combine them with markers explored in this and other studies, in order to evaluate their impact on vascular and/or congenital diseases.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652272     DOI: 10.1016/j.gene.2012.05.029

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients.

Authors:  Souhir Chaabane; Meriam Messedi; Rim Akrout; Mariem Ben Hamad; Mouna Turki; Sameh Marzouk; Leila Keskes; Zouheir Bahloul; Ahmed Rebai; Fatma Ayedi; Abdellatif Maalej
Journal:  Inflamm Res       Date:  2018-05-23       Impact factor: 4.575

Review 2.  Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis.

Authors:  Boyi Yang; Shujun Fan; Xueyuan Zhi; Yinuo Wang; Yanxun Wang; Quanmei Zheng; Guifan Sun
Journal:  Nutrients       Date:  2014-12-29       Impact factor: 5.717

3.  Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study.

Authors:  Aline Hajj; Sahar Obeid; Saria Sahyoun; Chadia Haddad; Jocelyne Azar; Lydia Rabbaa Khabbaz; Souheil Hallit
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

4.  Hyperhomocysteinemia accompany with metabolic syndrome increase the risk of left ventricular hypertrophy in rural Chinese.

Authors:  Shasha Yu; Yintao Chen; Hongmei Yang; Xiaofan Guo; Liqiang Zheng; Yingxian Sun
Journal:  BMC Cardiovasc Disord       Date:  2020-02-03       Impact factor: 2.298

5.  The prevalence, relative risk factors and MTHFR C677T genotype of H type hypertension of the elderly hypertensives in Shanghai, China: a cross-section study : Prevalence of H type hypertension.

Authors:  Bin Hong; Zhao-Qiang Cui; Jun-Bo Ge; Xiao-Lin Qian; Hong Cao; Jun Zhang; Zhi-Hui Gu; Wei-Qin Tang; Lei Shen; Jia-Lu Hu; Zhi-Feng Yao; Lei Zhang; Min-Na Tang; Xu-Cheng Lv; Jun Zhou; Xue-Juan Jin
Journal:  BMC Cardiovasc Disord       Date:  2021-08-04       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.